Sanofi Dupixent Freefield 200mg and 300mg(component name dupilumab, genetic recombination) have been expanded in health insurance benefits for children and adolescents aged 6 years or older since April 1.
Previously, the health insurance coverage of 300 milligrams of Dupigent Freefield, which was applied to severe atopic dermatitis patients aged 18 or older, was expanded to children and adolescents aged 6 or older, and 200 milligrams of Dupixent Freefield was newly listed on the salary list.
Through a phase 3 clinical study, DuPigent confirmed the effect of symptom control and consistent safety profile for children and adolescents aged 6 years or older and patients with moderate-severe atopic dermatitis. Accordingly, on January 12 of this year, the Drug Benefit Evaluation Committee of the Health Insurance Review and Assessment Service recognized the appropriateness of DuPixent's drug benefit.
Meanwhile, DuPixent is the first biopharmaceutical to target and control the signal transmission of interleukin-4 (IL-4) and interleukin-13 (IL-13), the main causative agents of type 2 inflammation. IL-4, IL-13 are known to be a key factor in type 2 inflammation, which is known to be the main cause of chronic nasal sinusitis accompanied by atopic dermatitis, asthma, and non-species.
